The ENERGY study is for adults (ages 18 and up) with warm Autoimmune Hemolytic Anemia (wAIHA) who are currently receiving treatment or have previously received treatment. The goal of the study is to see if the study drug, Nipocalimab is safe and effective in the treatment of wAIHA. Nipocalimab is an investigational medication designed to stop your immune system from destroying your red blood cells.

You may be able to join the study if you are:

• 18 years of age or older
• Diagnosed with wAIHA for at least 3 months
• Currently receiving treatment or have previously received treatment for wAIHA
• Have platelet counts of more than 30,000/ L and Hemoglobin less than 10 g/dL

Other study requirements will apply.

The LUNA 3 study is for teenagers and adults (ages 12 and up) with primary immune thrombocytopenia (ITP) for which standard medications are no longer working. The goal of the study is to see if the study drug, Rilzabrutinib can safely increase platelet counts and improve symptoms for people with ITP. Rilzabrutinib is an investigational medication designed to stop your immune system from destroying your platelets. You may be able to join the study if you are:

• 12 years of age or older.
• Diagnosed with primary ITP for at least 6 months for ages 12 through 17 or for at least 3 months for ages 18 and up.
• Have taken IVIg or steroids, but they are no longer working.
• Have platelet counts of less than 30,000.

Other study requirements will apply.

This research study is seeking participants who have hemophilia B and need regular preventive treatment with factor IX protein (FIX) replacement therapy to prevent and also control bleeding events. To join the study , you must be male as assigned at birth, and between the ages of 16 and 65 years at the time of signing the informed consent form. The purpose of this study is to gather at least 6 months of information on bleeding events for each individual participant while they continue to use their usual FIX replacement therapy. There is no experimental drug or treatment being tested in this study. The study is informational, and part of a larger program to understand and treat hemophilia B with a potential experimental new therapy in the future. After participants complete this research study, should they be interested and eligible, they may be offered the opportunity to take part in a future study with this new therapy. There is no obligation to agree to taking part in this future study.